Le Lézard
Classified in: Health, Science and technology
Subject: Funding

MANA Therapeutics Announces Final Closing of Series A and Closing of Venture Debt Facility


MANA Therapeutics, a clinical-stage company creating nonengineered, off-the-shelf allogeneic cell therapies that target multiple cancer antigens, today announced the final closing of its Series A financing, bringing the total raised to $42 million. In addition, MANA closed a $7.5 million venture debt facility with Silicon Valley Bank with an initial tranche of $5 million available immediately.

"This additional funding will enable us to accelerate the start of our clinical studies for our novel approach to off-the-shelf allogeneic cell therapy for patients with transplant-ineligible AML and select solid tumors," said Martin Silverstein, M.D., President and CEO of MANA Therapeutics. "It will also permit building out our pipeline of MANA-512 candidates, which will apply new sets of antigens to the EDIFY platform.

"In the meantime, MANA-312, an allogeneic donor-derived cell therapy candidate, has progressed steadily through the Phase 1 clinical trial that we initiated earlier this year. This is encouraging progress and the data we are collecting will inform the development of our off-the-shelf programs, including MANA-412, which is expected to advance into clinical trials in 2022," continued Dr. Silverstein.

"Next-generation cell therapies continue to be one of the most promising approaches in immuno-oncology, but face meaningful obstacles to be safely and economically available in an allogeneic format. MANA is utilizing its proprietary ManaMatch HLA matching protocol to build a bank of readily accessible nonengineered off-the-shelf therapies that could treat the majority of patients in targeted cancer indications and allow for repeat dosing," said Marc Cohen, Co-founder of Cobro Ventures and Co-founder and Executive Chairman of MANA Therapeutics.

The additional Series A funding comes from new investors J&W Partners, a South Korean private equity firm, and SK Securities, a leading securities firm in South Korea. As part of the agreement, J&W Partners will gain a seat on MANA's Board of Directors.

About EDIFYtm

MANA Therapeutics' EDIFYtm platform constitutes the next-generation cell therapy approach by leveraging natural immune system pathways to educate T-cells to target unique sets of antigens expressed by tumors, without the need for genetic modification. The EDIFY platform uses dendritic cells as antigen presenting cells. The dendritic cells are loaded with ManaMixtm antigens and stimulate and expand T-cells to generate product candidates. Product candidates developed from the EDIFY platform are designed to increase efficacy through multiple antigen targeting and to support a strong safety profile by utilizing a nonengineered approach that could permit for repeat dosing of patients. The EDIFY platform uses a simplified, high-yield manufacturing process.

About MANA Therapeutics

MANA Therapeutics is harnessing the natural immune system to develop broadly accessible, ready-to-use cellular therapies to improve outcomes for cancer patients. By educating T-cells to target multiple tumor associated antigens without the need for genetic modification, MANA's EDIFYtm platform provides the opportunity to deliver safe, effective, and repeatable therapies.

Our journey began with acute myeloid leukemia (AML) and we are advancing the science to develop additional proprietary and partnered programs for additional hematologic and solid tumors. https://www.manatherapeutics.com/


These press releases may also interest you

at 17:45
The "Cold Chain Monitoring - Global Strategic Business Report" has been added to  ResearchAndMarkets.com's offering. The global market for Cold Chain Monitoring estimated at US$7.3 Billion in the year 2023, is projected to reach a revised size of...

at 17:31
Sparkling Logic today announced the launch of AI Assistant, an interactive tool that enables users to complete decision management tasks through generative AI.An add-on to the SMARTStm decision management platform, AI Assistant provides guided,...

at 17:30
The "Business Travel - Global Strategic Business Report" has been added to  ResearchAndMarkets.com's offering. The global market for Business Travel estimated at US$690.6 Billion in the year 2023, is projected to reach a revised size of US$928.4...

at 17:28
The Federal Mediation and Conciliation Service (FMCS) is proud to announce the launch of its newest educational initiative: the "FMCS 101" video series. Designed to provide a comprehensive overview of the Agency's mission, services, and history, the...

at 17:26
NaaS Technology, the first U.S. listed EV charging service company in China, announced remarkable financial growth and operational highlights in its newly-released unaudited financial results for the fourth quarter and full year ended December 31,...

at 17:20
Adicet Bio, Inc. , a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted an inducement award on March 28, 2024. One individual was...



News published on and distributed by: